Noxxon Pharma develops biostable aptamers and substances based on mirror image nucleic acids.
NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 3, 2021 | Post-IPO Equity | €1.20M | 1 | — | — | Detail |
May 2, 2017 | Post-IPO Debt | €1M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Kreos Capital | — | Post-IPO Equity |